Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Share-based Compensation (2020 - 2025)

Historic Share-based Compensation for Roivant Sciences (ROIV) over the last 6 years, with Q4 2025 value amounting to $105.0 million.

  • Roivant Sciences' Share-based Compensation fell 4891.68% to $105.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $474.5 million, marking a year-over-year decrease of 120.07%. This contributed to the annual value of $289.0 million for FY2025, which is 4478.45% up from last year.
  • As of Q4 2025, Roivant Sciences' Share-based Compensation stood at $105.0 million, which was down 4891.68% from $81.8 million recorded in Q3 2025.
  • Roivant Sciences' Share-based Compensation's 5-year high stood at $487.8 million during Q4 2021, with a 5-year trough of $19.3 million in Q2 2021.
  • Moreover, its 5-year median value for Share-based Compensation was $81.8 million (2025), whereas its average is $138.6 million.
  • Within the past 5 years, the most significant YoY rise in Roivant Sciences' Share-based Compensation was 27777.78% (2022), while the steepest drop was 8440.04% (2022).
  • Quarter analysis of 5 years shows Roivant Sciences' Share-based Compensation stood at $487.8 million in 2021, then crashed by 60.54% to $192.5 million in 2022, then fell by 20.57% to $152.9 million in 2023, then surged by 34.43% to $205.5 million in 2024, then plummeted by 48.92% to $105.0 million in 2025.
  • Its last three reported values are $105.0 million in Q4 2025, $81.8 million for Q3 2025, and $82.2 million during Q2 2025.